PortfoliosLab logoPortfoliosLab logo
Edwards Lifesciences Corporation (EW)
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN
US28176E1082
CUSIP
28176E108
IPO Date
Mar 27, 2000

Highlights

Market Cap
$46.59B
Enterprise Value
$43.78B
EPS (TTM)
$1.83
PE Ratio
43.79
PEG Ratio
1.41
Total Revenue (TTM)
$6.07B
Gross Profit (TTM)
$4.74B
EBITDA (TTM)
$1.35B
Year Range
$65.94 - $87.89
Target Price
$96.38
ROA (TTM)
7.81%
ROE (TTM)
10.35%

Share Price Chart


Loading graphics...

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Edwards Lifesciences Corporation, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


Loading graphics...

S&P 500 Index

Returns By Period

Edwards Lifesciences Corporation (EW) has returned -6.06% so far this year and 10.49% over the past 12 months. Over the last ten years, EW has returned 10.33% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.


Edwards Lifesciences Corporation

1D
0.73%
1M
-7.39%
YTD
-6.06%
6M
2.97%
1Y
10.49%
3Y*
-1.08%
5Y*
-0.91%
10Y*
10.33%

Benchmark (S&P 500 Index)

1D
2.91%
1M
-5.09%
YTD
-4.63%
6M
-2.39%
1Y
16.33%
3Y*
16.69%
5Y*
10.18%
10Y*
12.16%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Monthly Returns

Based on dividend-adjusted daily data since Mar 27, 2000, EW's average daily return is +0.08%, while the average monthly return is +1.69%. At this rate, your investment would double in approximately 3.4 years.

Historically, 61% of months were positive and 39% were negative. The best month was May 2000 with a return of +35.4%, while the worst month was Oct 2000 at -38.4%. The longest winning streak lasted 8 consecutive months, and the longest losing streak was 4 months.

On a daily basis, EW closed higher 52% of trading days. The best single day was Jul 24, 2002 with a return of +17.9%, while the worst single day was Oct 31, 2000 at -41.4%.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2026-4.56%6.28%-7.39%-6.06%
2025-2.13%-1.15%1.20%4.15%3.62%-0.01%1.41%2.56%-4.39%6.02%5.12%-1.64%15.16%
20242.91%8.16%12.60%-11.40%2.62%6.31%-31.74%10.96%-5.67%1.55%6.48%3.76%-2.91%
20232.80%4.88%2.85%6.35%-4.26%11.99%-13.00%-6.82%-9.40%-8.03%6.26%12.61%2.20%
2022-15.71%2.90%4.76%-10.14%-4.66%-5.71%5.73%-10.38%-8.29%-12.34%6.65%-3.42%-42.41%
2021-9.48%0.63%0.65%14.20%0.40%8.00%8.40%4.37%-3.39%5.84%-10.44%20.73%42.00%

Benchmark Metrics

Edwards Lifesciences Corporation has an annualized alpha of 17.46%, beta of 0.71, and R² of 0.17 versus S&P 500 Index. Calculated based on daily prices since March 28, 2000.

  • This stock captured 104.87% of S&P 500 Index gains but only 54.02% of its losses — a favorable profile for investors.
  • R² of 0.17 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

Alpha
17.46%
Beta
0.71
0.17
Upside Capture
104.87%
Downside Capture
54.02%

Return for Risk

Risk / Return Rank

EW ranks 56 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.


EW Risk / Return Rank: 5656
Overall Rank
EW Sharpe Ratio Rank: 5757
Sharpe Ratio Rank
EW Sortino Ratio Rank: 5050
Sortino Ratio Rank
EW Omega Ratio Rank: 4747
Omega Ratio Rank
EW Calmar Ratio Rank: 6363
Calmar Ratio Rank
EW Martin Ratio Rank: 6565
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

Return / Risk — by metrics

The table below present risk-adjusted performance metrics for Edwards Lifesciences Corporation (EW) and compare them to a chosen benchmark (S&P 500 Index).


EWBenchmarkDifference

Sharpe ratio

Return per unit of total volatility

0.44

0.90

-0.46

Sortino ratio

Return per unit of downside risk

0.83

1.39

-0.56

Omega ratio

Gain probability vs. loss probability

1.10

1.21

-0.11

Calmar ratio

Return relative to maximum drawdown

1.02

1.40

-0.38

Martin ratio

Return relative to average drawdown

2.82

6.61

-3.79

Explore EW risk-adjusted metrics in detail

Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.

Dividends

Dividend History


Edwards Lifesciences Corporation doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading graphics...

Worst Drawdowns

The table below displays the maximum drawdowns of the Edwards Lifesciences Corporation. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Edwards Lifesciences Corporation was 54.32%, occurring on Jul 25, 2024. The portfolio has not yet recovered.

The current Edwards Lifesciences Corporation drawdown is 38.72%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-54.32%Dec 31, 2021644Jul 25, 2024
-50.48%Sep 1, 200043Nov 1, 2000165Jun 29, 2001208
-44.02%Oct 5, 2012299Dec 13, 2013217Oct 24, 2014516
-37.11%Feb 12, 2002112Jul 23, 2002199May 7, 2003311
-36.15%Nov 29, 201978Mar 23, 2020110Aug 27, 2020188

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading graphics...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Edwards Lifesciences Corporation over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how Edwards Lifesciences Corporation is priced in the market compared to other companies in the Medical Devices industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PE Ratio

The chart displays the Price-to-Earnings (P/E) ratio for EW, comparing it with other companies in the Medical Devices industry. Currently, EW has a P/E ratio of 43.8. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.

PEG Ratio

The chart shows the Price/Earnings to Growth (PEG) ratio for EW compared to other companies in the Medical Devices industry. EW currently has a PEG ratio of 1.4. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.

PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for EW relative to other companies in the Medical Devices industry. Currently, EW has a P/S ratio of 7.7. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for EW in comparison with other companies in the Medical Devices industry. Currently, EW has a P/B value of 4.5. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items